Amgen Inc. (AMGN) Position Decreased by Fayez Sarofim & Co.
Fayez Sarofim & Co. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 7.4% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 34,691 shares of the medical research company’s stock after selling 2,784 shares during the period. Fayez Sarofim & Co.’s holdings in Amgen were worth $5,278,000 as of its most recent filing with the SEC.
Several other hedge funds have also bought and sold shares of AMGN. Bank of Montreal Can purchased a new position in shares of Amgen during the second quarter valued at about $383,036,000. Wellington Management Group LLP increased its position in Amgen by 16.0% in the first quarter. Wellington Management Group LLP now owns 13,544,922 shares of the medical research company’s stock valued at $2,030,789,000 after buying an additional 1,864,688 shares during the last quarter. Nordea Investment Management AB increased its position in Amgen by 37.1% in the second quarter. Nordea Investment Management AB now owns 5,719,168 shares of the medical research company’s stock valued at $870,171,000 after buying an additional 1,547,099 shares during the last quarter. Emerald Acquisition Ltd. bought a new position in Amgen during the second quarter valued at $194,466,000. Finally, NN Investment Partners Holdings N.V. bought a new position in Amgen during the first quarter valued at $113,507,000. 79.15% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 166.81 on Friday. The firm has a market cap of $124.83 billion, a PE ratio of 17.07 and a beta of 0.87. The firm’s 50-day moving average price is $171.68 and its 200 day moving average price is $161.02. Amgen Inc. has a 52 week low of $138.06 and a 52 week high of $176.85.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.74 by $0.10. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.57 EPS. Equities analysts anticipate that Amgen Inc. will post $11.36 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were given a $1.00 dividend. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 annualized dividend and a yield of 2.40%. Amgen’s dividend payout ratio is currently 40.90%.
Several equities analysts have weighed in on the company. BMO Capital Markets reissued an “outperform” rating and set a $190.00 price target on shares of Amgen in a research report on Thursday, September 22nd. Jefferies Group reissued a “buy” rating and set a $198.00 price target on shares of Amgen in a research report on Tuesday, August 23rd. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target for the company in a research report on Wednesday, August 3rd. Leerink Swann reissued a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Finally, Credit Suisse Group AG set a $206.00 price target on Amgen and gave the stock a “buy” rating in a research report on Saturday, September 17th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $185.06.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the business’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.20% of the stock is currently owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.